Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-&amp;epsilon;-poly(caprolactone) nanocarriers

Wang, Zhiyu; Wei, Yuying; Fang, Guotao; Hong, Daojun; An, L.; Jiao, Ting; Shi, Yan; Zang, Aimin

doi:10.2147/dddt.s175614

Cited by 30 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that the DNA release was faster than drug release in the same kind of LPNs, this may be explained by the loading of gene was at the outer layer of the LPNs. 21 In vitro Cellular Uptake and Cytotoxicity Figure 4A illustrated that the cellular uptake of HA-I/ D-LPNs was higher than I/D-LPNs (P < 0.05), which may be the evidence that HA-I/D-LPNs have CD44-targeting effect. 41 In vitro cytotoxicity results showed that HA-I/ D-LPNs exhibited remarkable better cell inhibition .…”

Section: In Vitro Drug and Gene Releasementioning

confidence: 92%

“…[18][19][20] In our previous study, colorectal cancer was treated with 5-Fluorouracil (5-FU) and enhanced GFP (EGFP) codelivered polymeric nanoparticles and achieved effective combination results. 21 Lipid nanoparticles/liposomes are biocompatible and can be used for the specific delivery of gene/drug to tumor tissues and also render them long circulatory lifetime. 22 In the research carried out by Han et al, plasmid DNA and doxorubicin were co-delivered by solid lipid nanoparticles for lung cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

Self Cite

View full text Add to dashboard Cite

Background: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy. Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model. Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (C max) and half-life (T 1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/ D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo. Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.

show abstract

Section: In Vitro Drug and Gene Releasementioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, combination therapy, including co-delivery of drug and gene by NPs have attracted more attention these years [244,245]. Wang et al [116], investigated the potential of co-loaded NPs with anticancer drugs and genes as a promising strategy for colorectal cancer therapy. They used poly (ethylene glycol)-ε-poly(caprolactone) block copolymer for co-loading of 5-fluorouracil (5-FU) and pEGFP (DNA) as DFNC.…”

Section: Colorectal Cancer Therapymentioning

confidence: 99%

“…Significant inhibiting tumor growth [116] PAMAM [133] (continued on next page) (continued on next page)…”

Section: Introductionmentioning

confidence: 99%

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad

Dehshahri

Madamsetty

et al. 2020

Journal of Controlled Release

192

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…Cytotoxicity of LPNs. Cytotoxicity of the LPNs was evaluated on A549 cells by MTT assay (32). Cells (2x10 5 per well) were seeded into 6-well microplates and allowed to grow for 24 h to a subconfluent state.…”

Section: Stability Of Lpnsmentioning

confidence: 99%

Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin

Yan

2019

Oncol Rep

View full text Add to dashboard Cite

The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor tumor tissue drug accumulation and nonspecific cytotoxicity. Epidermal growth factor receptor (EGFR) is a promising target, which is overexpressed in lung carcinomas. In the present study, EGFR-targeted nanoparticles were constructed and co-delivered cisplatin (CDDP) and doxorubicin (DOX) for lung cancer therapy. In the present research, EGF-PEG-DSPE was synthesized. Then, EGFR-targeted lipid polymeric nanoparticles (LPNs) were fabricated, which consisted of a CDDP-loaded hybrophobic polymeric core, a DOX-loaded phospholipid layer, and an outer layer of EGF-PEG-DSPE ligand. The particle size, ζ potential, stability, release behavior of LPNs were characterized. The antitumor ability of LPNs were assessed in vitro and in vivo. EGFR-targeted LPNs loaded with CDDP and DOX (EGF C/D LPNs) had a size of 141.6 nm, and could encapsulate over 80% of feed drugs. Dual drug-loaded LPNs showed synergistic effects with a combination index (CI) of 0.57. EGF C/D LPNs showed the smallest tumor volume (253 mm 3), with a tumor inhibition ratio of 74.5%. In summary, EGF C/D LPNs were stable and released the drugs in a sustained manner. In vitro and in vivo studies revealed that EGF C/D LPNs exhibited improved anticancer activity along with lower toxicity. These results indicated the best efficiency of EGF C/D LPNs for lung carcinoma therapy.

show abstract

Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers

Cited by 30 publications

References 42 publications

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin

Contact Info

Product

Resources

About